EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm

Angelo Torrente, Paolo Alonge, Antonia Pignolo, Eloise Lo Mauro, Roberto Monastero, Angelo Labate

Neurological Sciences · 2026-07 · 47 (7)

DOI: 10.1007/s10072-026-09172-4 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Neurological Sciences, online erschienen am 15.06.2026. Verfasst von Angelo Torrente und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy. Hauptthemen laut MEDLINE: Clonazepam, Blepharospasm, GABA Modulators. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Palermo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Benign Essential Blepharospasm (BEB) is a focal dystonia that leads to an increased rate of eyelid closure due to involuntary activation of the orbicularis oculi muscles. In severe cases, daily activities can significantly be affected, with reduced quality of life. Injections of OnabotulinumtoxinA are often used as valid therapeutical option. However, this treatment may not be tolerated by all patients, considering its invasive nature and the need for access to specialized centers. Despite oral agents, such as benzodiazepines (particularly clonazepam), are often used as a first-line treatment, evidence regarding their efficacy remains fragmentary.

Objective

This scoping review aims to evaluate the current evidence for the efficacy of clonazepam for benign essential blepharospasm.

Methods

Articles in English about the use of clonazepam in the treatment of BEB were searched for in three major databases (PubMed, Scopus, Cochrane).

Results

The search yielded 259 results. After screening, 13 papers were sought for retrieval. After assessing their suitability, 2 articles were included in the review: one open-label trial and one case report. Despite some limitations, both showed the effectiveness of clonazepam in BEB.

Conclusion

Although some evidence supports the use of clonazepam in the treatment of BEB, high-quality studies are still needed to clarify aspects such as response rates, optimal dose, and other disease management issues. This information may be useful for clinicians who are unable to refer their patients to specialized centers and must rely on their own experience and anecdotal evidence for patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClonazepamBlepharospasmGABA ModulatorsHumansTreatment Outcome

Stichwörter der Autor:innen

Benign essential blepharospasmBenzodiazepinesClonazepamDystonia

Substanzen

ClonazepamGABA Modulators

Autor:innen und Institutionen

  • Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy.
  • Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, Palermo, Italy. roberto.monastero@unipa.it.

Förderung

  • Università degli Studi di Palermo

Zitieren

APA

Torrente, A., Alonge, P., Pignolo, A., Lo Mauro, E., Monastero, R., & Labate, A. (2026). A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm. Neurological Sciences, 47(7). https://doi.org/10.1007/s10072-026-09172-4

Vancouver

Torrente A, Alonge P, Pignolo A, Lo Mauro E, Monastero R, Labate A. A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm. Neurological Sciences. 2026;47(7). doi:10.1007/s10072-026-09172-4

BibTeX
@article{Torrente2026,
  author = {Torrente, Angelo and Alonge, Paolo and Pignolo, Antonia and Lo Mauro, Eloise and Monastero, Roberto and Labate, Angelo},
  title = {A scoping review about the efficacy of clonazepam for the treatment of benign essential blepharospasm},
  journal = {Neurological Sciences},
  year = {2026},
  volume = {47},
  number = {7},
  doi = {10.1007/s10072-026-09172-4}
}
Kostenlos starten →